Insulin-degrading enzyme

Insulin-degrading enzyme (IDE), also known as insulysin or insulinase, is a highly conserved zinc-metalloprotease that plays a critical role in the regulation of insulin levels and has implications in various diseases, including diabetes and Alzheimer's disease. IDE selectively degrades several peptides, including insulin, glucagon, amylin, and the amyloid β-protein, suggesting its broad physiological significance.

Function

IDE is primarily known for its role in the degradation of insulin, thereby regulating blood glucose levels. However, its ability to degrade other peptides, such as amyloid β, implicates it in the pathogenesis of Alzheimer's disease. By degrading amyloid β, IDE helps prevent the formation of amyloid plaques, a hallmark of Alzheimer's disease. Additionally, IDE is involved in the degradation of other biologically active peptides, including glucagon, amylin, and somatostatin, further underscoring its importance in metabolic regulation.

Structure

IDE is a zinc-metalloprotease, meaning it requires zinc to catalyze the hydrolysis of peptide bonds. The enzyme is a large, asymmetric homotetramer, with each subunit containing a zinc-binding site essential for its proteolytic activity. The structure of IDE reveals a large internal chamber, where peptide substrates bind and are subsequently degraded. This unique structural feature allows IDE to accommodate and degrade peptides of various sizes and sequences.

Clinical Significance

1. 1. 1. Diabetes Mellitus ###

In the context of diabetes, IDE's role in insulin degradation is of particular interest. Abnormalities in IDE function or expression could lead to altered insulin levels, contributing to the hyperglycemia characteristic of diabetes. Therapeutic strategies aimed at modulating IDE activity could potentially offer new avenues for diabetes treatment.

1. 1. 1. Alzheimer's Disease ###

IDE's ability to degrade amyloid β-protein links it to Alzheimer's disease. Reduced IDE activity or expression could impair amyloid β clearance, leading to plaque formation and neuronal toxicity. Enhancing IDE activity represents a potential therapeutic strategy for Alzheimer's disease, aiming to reduce amyloid β levels and mitigate disease progression.

Genetic Aspects

The gene encoding IDE is located on chromosome 10 in humans. Variations in this gene have been studied for associations with diabetes and Alzheimer's disease risk, although results have been mixed. Understanding the genetic regulation of IDE could provide insights into its role in disease and identify potential targets for therapeutic intervention.

Future Directions

Research into IDE continues to uncover its multifaceted roles in metabolism and disease. Future studies are likely to focus on elucidating the detailed mechanisms of IDE action, its interactions with various substrates, and the regulation of its activity and expression. Additionally, the development of IDE inhibitors or activators as potential therapeutic agents for diabetes and Alzheimer's disease represents a promising area of investigation.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian